Form 8-K - Current report:
SEC Accession No. 0001438533-25-000025
Filing Date
2025-05-01
Accepted
2025-05-01 16:05:51
Documents
15
Period of Report
2025-05-01
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tvtx-20250501.htm   iXBRL 8-K 34464
2 EX-99.1 a2025q1_8-kxex991.htm EX-99.1 175138
6 GRAPHIC imagea.jpg GRAPHIC 12958
  Complete submission text file 0001438533-25-000025.txt   377364

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tvtx-20250501.xsd EX-101.SCH 1782
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tvtx-20250501_lab.xml EX-101.LAB 22804
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tvtx-20250501_pre.xml EX-101.PRE 13046
17 EXTRACTED XBRL INSTANCE DOCUMENT tvtx-20250501_htm.xml XML 3024
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

EIN.: 262383102 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36257 | Film No.: 25903009
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)